Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.

Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.

Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.

Abstract: The invention relates to pharmaceutical compositions containing rosuvastatin calcium of formula (I) and processes for their manufacture.

Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.

Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.

Abstract: Oral dosage form containing a therapeutically effective amount of a drug susceptible to abuse and an effective amount of an embolizing agent which causes the production of a solid or semi-solid embolus or blockage after tampering.

Abstract: Parenteral extravascular administration of a composition containing an analgesic medication of low water solubility that is dissolved, suspended, or emulsified in a solvent system results in the deposition of the analgesic medication at the site of administration and provides a controlled release of the analgesic medication from the site and a prolonged analgesia that may persist for several days following administration.

Abstract: Compositions containing a vehicle containing a rosin resin or derivative and a non-volatilized solvent or plasticizer. The compositions may be used to deliver a biologically active substance such as an active pharmaceutical ingredient. The concentration of rosin resin or derivative in the vehicle is sufficient to alter the release rate from the composition of a biologically active substance that is dissolved, dispersed, emulsified, or suspended in the vehicle.

Abstract: A dosage form from which a burst release of a drug contained within a tampered dosage form is reduced or retarded by the presence in or on the dosage form of a TPTA (Tamper Prone Therapeutic Agent) trap. If the dosage form has not been tampered with, the TPTA trap does not significantly interfere with the rate of release of the drug from the dosage form. However, if the dosage form has been physically tampered with, the TPTA trap reduces or retards burst release of the drug from the dosage form.

Abstract: Methods for making granules containing a carbomer whereby the carbomer is mixed with a hot-melt binder that does not lower the glass transition temperature of the carbomer more than 20° C., the binder is subjected to a temperature at which the hot-melt binder melts or becomes tacky, thus binding the carbomer to form an agglomerated powder, and permitting granules to form from the agglomerated powder. This subjecting of the binder to the temperature may be after the binder is mixed with the carbomer or the carbomer may be mixed with the binder at a time when the binder is at a temperature at which it will melt or become tacky. The granules may contain a biologically active substance either intragranularly or extragranularly and may be used to make personal care products or pharmaceutical dosage forms, such as controlled release dosage forms which may have bioadhesive properties.

Abstract: A method for making granules containing a biologically active substance (BAS) whereby the BAS is mixed with a binder to form a powder mixture having a concentration of binder below that which, when the binder is melted, will cause over-wetting of the powder mixture, heating the mixture to a temperature above the melting point of the binder to form an agglomerated powder, and forming granules from the agglomerated powder. The granules may be used to make pharmaceutical dosage forms such as tablets and capsules.